Chu Xin
Chu Xin has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Chenxi Wu
Chengdu Univ Tradit Chinese Med, Coll Nursing, Chengdu, Peoples R China
1 shared publicationDongmei Cheng
Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
1 shared publicationGuo Dongqing
School of Nursing, Chengdu University of Traditional Chinese Medicine
1 shared publicationHe Yan
School of Nursing, Chengdu University of Traditional Chinese Medicine
1 shared publicationKexin Tang
Chengdu Univ Tradit Chinese Med, Coll Nursing, Chengdu, Peoples R China
1 shared publicationLi Nana
School of Nursing, Chengdu University of Traditional Chinese Medicine
1 shared publication
Latest Publications
- Open Access
- 24 February 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1672180
Incidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect in cancer patients, yet studies have reported inconsistent incidence and influencing factors for CIPN. This study aims to systematically evaluate the incidence and influencing factors of CIPN in cancer patients. Methods: The search databases included PubMed, Embase, Cochrane Library, and Web of Science, focusing on CIPN incidence and influencing factors in cancer patients up to 10 June, 2025. A meta-analysis of incidence and influencing factors was performed separately by Stata 17.0 software. Results: 23 studies involving a sample size of 15,090 cases were included, and 16 influencing factors were identified. The incidence of CIPN in cancer patients was 56% (95% CI: 46–66%, p < 0.01). Age ≥50 years ( OR = 1.07, 95% CI: 1.03–1.10), BMI ≥ 24 kg/m 2 ( OR = 1.15, 95% CI: 1.06–1.24), BMI ≥ 30 kg/m 2 ( OR = 1.67, 95% CI: 1.43–1.95), anxiety or depression ( OR = 2.50, 95% CI: 1.20–5.20), hypertension ( OR = 1.98, 95% CI: 1.07–3.69), diabetes mellitus ( OR = 1.66, 95% CI: 1.29–2.13), cumulative dose of chemotherapy drugs ( OR = 2.52, 95% CI: 1.20–5.32), chemotherapy≥4 cycles ( OR = 1.21, 95% CI: 1.08–1.35), combination with taxane chemotherapy (per 10 mg/m 2 ) ( OR = 3.14, 95% CI: 1.81–5.44), vitamin D deficiency ( OR = 5.63, 95%CI: 2.64–11.99), high cholesterol ( OR = 1.34, 95% CI: 1.14–1.58), and transaminase elevation ( OR = 2.10, 95% CI: 1.55–2.84) were influencing factors for CIPN in cancer patients. Conclusion: The results show that the incidence of CIPN in cancer patients is at a high level, and its influencing factors are varied and complex. This suggests that clinicians should screen for CIPN early to improve clinical outcomes and enhance the quality of life and survival for cancer patients. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , CRD420251010306.
- 24 February 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1672180
Open AccessIncidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect in cancer patients, yet studies have reported inconsistent incidence and influencing factors for CIPN. This study aims to systematically evaluate the incidence and influencing factors of CIPN in cancer patients. Methods: The search databases included PubMed, Embase, Cochrane Library, and Web of Science, focusing on CIPN incidence and influencing factors in cancer patients up to 10 June, 2025. A meta-analysis of incidence and influencing factors was performed separately by Stata 17.0 software. Results: 23 studies involving a sample size of 15,090 cases were included, and 16 influencing factors were identified. The incidence of CIPN in cancer patients was 56% (95% CI: 46–66%, p < 0.01). Age ≥50 years ( OR = 1.07, 95% CI: 1.03–1.10), BMI ≥ 24 kg/m 2 ( OR = 1.15, 95% CI: 1.06–1.24), BMI ≥ 30 kg/m 2 ( OR = 1.67, 95% CI: 1.43–1.95), anxiety or depression ( OR = 2.50, 95% CI: 1.20–5.20), hypertension ( OR = 1.98, 95% CI: 1.07–3.69), diabetes mellitus ( OR = 1.66, 95% CI: 1.29–2.13), cumulative dose of chemotherapy drugs ( OR = 2.52, 95% CI: 1.20–5.32), chemotherapy≥4 cycles ( OR = 1.21, 95% CI: 1.08–1.35), combination with taxane chemotherapy (per 10 mg/m 2 ) ( OR = 3.14, 95% CI: 1.81–5.44), vitamin D deficiency ( OR = 5.63, 95%CI: 2.64–11.99), high cholesterol ( OR = 1.34, 95% CI: 1.14–1.58), and transaminase elevation ( OR = 2.10, 95% CI: 1.55–2.84) were influencing factors for CIPN in cancer patients. Conclusion: The results show that the incidence of CIPN in cancer patients is at a high level, and its influencing factors are varied and complex. This suggests that clinicians should screen for CIPN early to improve clinical outcomes and enhance the quality of life and survival for cancer patients. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , CRD420251010306.
- 14 December 2023
- Published by Elsevier in Journal of Pediatric Nursing
- Vol. 75, 31-40
Caregiving experiences of caregivers of children with rare diseases: A qualitative meta-synthesis
- 14 December 2023
- Published by Elsevier in Journal of Pediatric Nursing
- Vol. 75, 31-40
Caregiving experiences of caregivers of children with rare diseases: A qualitative meta-synthesis